Literature DB >> 9124839

Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.

E M Thorpe1, J R Schwebke, E W Hook, A Rompalo, W M McCormack, K L Mussari, G C Giguere, J J Collins.   

Abstract

A randomized, multicenter, investigator-blind trial was conducted to compare the efficacies of cefuroxime axetil and ciprofloxacin for treatment of patients with uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). A total of 832 patients (434 females and 398 males) received a single oral dose of cefuroxime axetil (1,000 mg [417 patients]) or ciprofloxacin (500 mg [415 patients]). N. gonorrhoeae was eradicated from the cervix in 114 of 118 (97%) and 118 of 119 (99%) bacteriologically evaluable females treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.213; difference, -2%; 95% confidence interval, -6 to 1%), and from the urethra in 154 of 166 (93%) and 171 of 171 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P < 0.001; difference, -7%; 95% confidence interval, -11 to -3%). Both treatments were effective in eradicating N. gonorrhoeae in females with rectal infections (cefuroxime axetil, 29 of 30 [97%]; ciprofloxacin, 25 of 25 [100%]; P = 1.00). In small numbers of patients, cefuroxime axetil was less effective than ciprofloxacin in treating males with pharyngeal infections (eradication in 4 of 10 and in 8 of 8 patients, respectively; P = 0.013). PPNG was eradicated from the cervix in 22 of 23 (96%) and 32 of 32 (100%) bacteriologically evaluable female patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 0.418; difference, -4%; 95% confidence interval, -13 to 4%), and from the urethra in 35 of 36 (97%) and 34 of 34 (100%) bacteriologically evaluable male patients treated with cefuroxime axetil and ciprofloxacin, respectively (P = 1.00; difference, -3%; 95% confidence interval, -8 to 3%). The incidences of drug-related adverse events were similar for the two study drugs. In summary, treatment with a single oral dose of cefuroxime axetil is as effective as treatment with a single oral dose of ciprofloxacin in eradicating PPNG from males and females with uncomplicated gonorrhea (urethral and endocervical), and both regimens are well-tolerated. However, in the present study, cefuroxime axetil was less effective than ciprofloxacin in treating urethral gonococcal infections in male patients, although both study drugs were highly effective in treating cervical gonococcal infections in female patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124839      PMCID: PMC163620     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Therapy for gonococcal infections: options in 1989.

Authors:  J S Moran; J M Zenilman
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

2.  Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993.

Authors:  J S Knapp; J A Washington; L J Doyle; S W Neal; M C Parekh; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Cefuroxime axetil for treatment of uncomplicated gonorrhea.

Authors:  A Gottlieb; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

4.  A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group.

Authors:  H H Handsfield; W M McCormack; E W Hook; J M Douglas; J M Covino; M S Verdon; C A Reichart; J M Ehret
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

5.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

6.  Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii.

Authors:  J S Knapp; R Ohye; S W Neal; M C Parekh; H Higa; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women.

Authors:  L M Baddour; R S Gibbs; G Mertz; D M Cocchetto; R C Noble
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 8.  Cefuroxime: antimicrobial activity, Pharmacology, and clinical efficacy.

Authors:  B R Smith; J L LeFrock
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

Review 9.  Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions and therapeutic indications.

Authors:  B Gold; W J Rodriguez
Journal:  Pharmacotherapy       Date:  1983 Mar-Apr       Impact factor: 4.705

10.  Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial.

Authors:  R C Reichman; F S Nolte; S M Wolinsky; C A Greisberger; M A Trupei; J Nitzkin
Journal:  Sex Transm Dis       Date:  1985 Oct-Dec       Impact factor: 2.830

View more
  3 in total

1.  Differential intracellular efficacies of ciprofloxacin and cefixime against Neisseria gonorrhoeae in human fallopian tube organ culture.

Authors:  J P Phanucharas; G L Gorby
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 2.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.